Quanterix
Update in progressQTRX (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryMedical Devices
Quanterix Corporation develops and sells Simoa-based instruments and assays for life science research and clinical testing. Its HD-X, SR-X, and SP-X platforms enable ultra-sensitive protein detection and multiplex immunoassays. The company provides complete assay kits, reagents, parts, and antibodies, plus contract research and clinical laboratory services. Headquartered in Billerica, Massachusetts; formerly Digital Genomics, Inc.
Company score
- Sentiment
- 0.21
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.20
- Governance
- 0.06
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.14
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEOMr. Everett V. Cunningham
- Founded2007
- Employees450
- Websitewww.quanterix.com
Identifiers
- ISINUS74766Q1013
- FIGIBBG0027NWC69
- CUSIP74766Q101
- CIK0001503274